Menu
Clinical trials for the treatment of prostate cancer
Before the Q-PRO® system can be commercialised, the treatment must be proven to be effective, safe and provide the intended clinical effect. We run a clinical trial for patients with prostate cancer recurrence, conducted by eminent doctors at leading prostate cancer clinics, in North America and Europe. We are in the process of starting another clinical trial, for patients with primary localised prostate cancer.
University College London Hospital
Memorial Sloan Kettering Cancer Center
Princess Margaret Cancer Center
Skånes universitetssjukhus
The goal of the trials
The goal of the trials is to investigate the effect of the treatment, to determine the optimal dose of laser light and drug and to investigate how safe the use of laser treatment in combination with the medicinal substance verteporfin is.
Trial for prostate cancer recurrence
We follow a clear development strategy and have initially started a clinical trial for patients who have relapsed from prostate cancer, after previously undergoing radiotherapy. The clinical trial is carried out by prominent doctors at leading prostate cancer clinics: Princess Margaret Cancer Center in Toronto, University College London Hospital, Memorial Sloan Kettering Cancer Center in New York and at Skåne University Hospital in Malmö. Through leading doctors and reference clinics, SpectraCure builds important clinical evidence to gain acceptance for the treatment in the future.
Trial for primary localised prostate cancer
The work to initiate a clinical trial for the indication primary localised prostate cancer with medium-to-high risk has begun. The new trial signifies the broadening of the recruitment base and addresses a significantly larger market. The trial will run parallell to the first trial for prostate cancer recurrence. The clinical trial for prostate cancer recurrence has been strategically important in planning the trial for primary localised prostate cancer.
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.